Last reviewed · How we verify
Tandospirone Citrate
Tandospirone Citrate, marketed by Zhejiang Provincial People's Hospital, is an established drug in the pharmaceutical market with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it from other treatments. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Tandospirone Citrate |
|---|---|
| Sponsor | Zhejiang Provincial People's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder (PHASE4)
- A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tandospirone Citrate CI brief — competitive landscape report
- Tandospirone Citrate updates RSS · CI watch RSS
- Zhejiang Provincial People's Hospital portfolio CI